How does the 30,000-share stock option for Summit Therapeutics (SMMT) vest?

The 30,000-share option granted on January 8, 2026 vests in four equal annual installments , with the first installment vesting on January 8, 2027 .

Summit Therapeutics (SMMT) grants CAO stock option for 30,000 shares

Q: What insider transaction did Summit Therapeutics (SMMT) report for Anand Bhaskar?

Summit Therapeutics reported that Chief Accounting Officer Anand Bhaskar received a grant of a stock option to buy 30,000 shares of the company’s common stock.

Q: What does this Form 4 filing for Summit Therapeutics (SMMT) represent?

This Form 4 reports an option grant to a company officer, disclosing the number of shares , exercise price , vesting schedule , and expiration date of the award.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Summit Therapeutics Inc. reported that its Chief Accounting Officer, Anand Bhaskar, received a stock option grant. On January 8, 2026, Bhaskar was awarded an option to purchase 30,000 shares of Summit Therapeutics common stock at an exercise price of $18.83 per share.

The option becomes exercisable over time, vesting in four equal annual installments, with the first installment scheduled to vest on January 8, 2027. The option expires on January 8, 2036. Following this grant, Bhaskar beneficially owns 30,000 derivative securities directly in the form of this stock option.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Anand Bhaskar

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	30,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 30,000 shares (Direct)

Footnotes (1)

The option was granted on January 8, 2026. The shares underlying the option shall vest in four equal annual installments, with the first such installment occurring on January 8, 2027. Not applicable.

Form 4 Insider Transactions: What Each Field Means →

01/12/2026 - 04:01 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anand Bhaskar

(Last)

(First)

(Middle)

C/O SUMMIT THERAPEUTICS INC.

601 BRICKELL KEY DRIVE, SUITE 1000

(Street)

MIAMI

33131

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Summit Therapeutics Inc. [ SMMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$18.83	01/08/2026		A		30,000		⁽¹⁾	01/08/2036	Common Stock	30,000	⁽²⁾	30,000	D

Explanation of Responses:

1. The option was granted on January 8, 2026. The shares underlying the option shall vest in four equal annual installments, with the first such installment occurring on January 8, 2027.

2. Not applicable.

Remarks:

	/s/ Bhaskar Anand	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Summit Therapeutics (SMMT) report for Anand Bhaskar?

Summit Therapeutics reported that Chief Accounting Officer Anand Bhaskar received a grant of a stock option to buy 30,000 shares of the company’s common stock.

What is the exercise price of Anand Bhaskar’s Summit Therapeutics (SMMT) stock option?

The stock option granted to Anand Bhaskar has an exercise price of $18.83 per share for the underlying Summit Therapeutics common stock.

When does Anand Bhaskar’s Summit Therapeutics (SMMT) stock option expire?

The stock option granted to Anand Bhaskar is scheduled to expire on January 8, 2036, if not exercised earlier in accordance with its terms.

How many Summit Therapeutics (SMMT) derivative securities does Anand Bhaskar own after this Form 4?

After the reported transaction, Anand Bhaskar beneficially owns 30,000 derivative securities, all in the form of this directly held stock option.

What does this Form 4 filing for Summit Therapeutics (SMMT) represent?

This Form 4 reports an option grant to a company officer, disclosing the number of shares, exercise price, vesting schedule, and expiration date of the award.